Kornimate/medical-research-clean huggingface dataset:
intensive motor training after perinatal stroke to enhance walking

Conditions: Perinatal Stroke

Summary: early childhood injuries such as perinatal (around birth) stroke are devastating because the child lives with the problem for life, typically close to a normal lifespan. one 'opportunity' presented by a brain injury early in life compared to later in adulthood is that the young brain is much more plastic (malleable) and receptive to interventions. this is particularly true for neural circuits that are still under development. we will test the hypothesis that early (\ 2 yr old. we will further determine the changes induced by training in motor and sensory pathways.

children 8 mo to 3 yr old with unilateral perinatal stroke will be randomized into either: 1) immediate training, or 2) delayed training groups. the immediate group will train for 3 mo shortly after recruitment. the delayed group will go through the same measurements from the time of recruitment and at 3 mo later (with no training in between) to obtain a 3 mo change score which will serve as a control measure for the immediate group. the delayed group will also train after the 3 mo delay, when all control measures have been taken. comparison of the improvements made by children who started training \ 2 yr old will answer the question if training at \ 2 yr old. finally, to determine if there are long term effects of this training, we will compare outcomes of these trained children with another group of children with the same injuries but no intensive training (i.e., too old for the training study), when all children turn 4 yr old. clinical, kinematic and electrophysiological measures will be taken to help us understand not only the efficacy of the treatment, but also the neural mechanisms that might underlie improvements in outcome. we are measuring outcomes at multiple times because change scores are of most interest. all children change as they age, so it is critical that we compare the change score with and without intervention.

Eligibility criteria:
inclusion criteria: * hemiplegia with confirmation of perinatal stroke through magnetic resonance imaging * born near term (\> or equal to 36 weeks gestation) * current age between 8 months to 3.0 years old; or currently 4 years old (control) * no other neurological disorders * informed consent from parent or guardian exclusion criteria: * central nervous system injury besides the one-sided stroke * musculoskeletal problems that limit leg activity * cognitive, behavioral or developmental impairments that preclude participation in the protocol * unstable epileptic seizures within the last 6 months * any contraindications to transcranial magnetic stimulation * botox injection in the legs over the last 6 months

Keywords: cerebral palsy physical therapy rehabilitation hemiplegia
comparative effects of ciprofol and propofol on pain intensity on the first day after surgery: a retrospective, propensity score matched, cohort study

Conditions: Anesthesia; Acute Pain; Risk Reduction

Summary: data intelligence platform was widely used to facilitate the process of clinical research. however, a platform that integrates natural language processing (nlp) and machine learning (ml) algorithms has not been reported in perioperative medical management.


Eligibility criteria:
inclusion criteria: * patients were included if they were above 18 years old, undergoing non-local anesthesia surgery. exclusion criteria: * the basic information such gender, age, height, weight, and body mass index (bmi) were missing. * patients undergoing day surgery, with a history of multiple operations, or entering icu after surgery, and losing the nrs score during movement at 24h after surgery.

Keywords: data platform machine learning postoperative acute pain
influenza associated aspergillosis in-depth investigation

Conditions: Influenza With Pneumonia; Invasive Pulmonary Aspergillosis

Summary: this trial is aimed to study the immunological and pathological characteristics of influenza versus non-influenza severe community-acquired pneumonia patients in icu.

this trial is aimed to study the immunological and pathological characteristics of influenza versus non-influenza severe community-acquired pneumonia patients in icu, and correlate findings with occurrence of secondary invasive pulmonary aspergillosis infection. all consecutive patients aged 18 or older admitted to icu during the inclusion period with respiratory distress due to influenza positive/negative community acquired pneumonia (cap) will be included.

Eligibility criteria:
inclusion criteria: * all patients older than 18 years, admitted to icu with respiratory distress with microbiologically confirmed diagnosis of influenza (for inclusion in the influenza group) * all patients older than 18 years, admitted to icu for respiratory distress due to community- acquired pneumonia , with a microbiologically confirmed absence of influenza (for inclusion in the control group) exclusion criteria: * age \< 18 years old * pregnant women * no informed consent

Keywords: influenza ipa icu immunology
prediction of post-tips hepatic encephalopathy in patients with liver cirrhosis

Conditions: Hepatic Encephalopathy; Liver Cirrhosis

Summary: prediction of hepatic encephalopathy after insertion of a transjugular intrahepatic portosystemic stent shunt (post-tips he) are critical for patient selection prior to tips insertion, and a currently unmet, clinically highly relevant need. in this prospective multicenter observational cohort study, the investigators aim to evaluate the ability of stroop encephalapp and the simplified animal naming test (s-ant1) in comparison to the goldstandard phes to predict the occurence of post-tips he in patients with decompensated liver cirrhosis. moreover, secondary aims of this study include the detection of potential blood based biomarkers for prediction of post-tips he and the predictive value of frailty and quality of life/sleep prior to tips insertion.


Eligibility criteria:
inclusion criteria: * liver cirrhosis (clinical, sonographic, ct-morphological, laparoscopic or histological) * tips indication: refractory ascites or secondary prophylaxis after variceal bleeding * age ≥ 18 years * ability to give consent * consent to the study after comprehensive information exclusion criteria: * contraindication against tips insertion * lack of consent * history of liver transplantation * preemptive tips * emergency tips * severe neurological comorbidities

Keywords: liver cirrhosis hepatic encephalopathy transjugular intrahepatic portosystemic shunt tips post-tips hepatic encephalopathy post-tips he minimal hepatic encephalopathy
study with healthy japanese and non-asian participants with bms-986231

Conditions: Heart Decompensation, Acute

Summary: the purpose of this phase 1 study is to evaluate the safety, tolerability, pk, and pharmacodynamics (pd) of bms-986231 in healthy japanese and non-asian participants. there is no formal hypothesis to be statistically tested.


Eligibility criteria:
inclusion criteria: * ancestry * first generation japanese * non-asian with grandparents and parents of non-asian descent * body weight greater than or equal to 45kg and less than or equal to 110kg * women of childbearing potential have specific birthcontrol methods * males sexually active with women of childbearing potential have specific birthcontrol methods exclusion criteria: * history of chronic illness * chronic headaches * recurrent dizziness * personal or family history of heart disease * personal history of bleeding diathesis
pedicled seromuscular flap for enforcement of high risk intestinal anastomoses

Conditions: Peritonitis

Summary: this is a control matched prospective study evaluating the use of seromuscular flap for high risk anastomoses.

30 eligible patients have been enrolled in the study then each case was matched to a control of patients who undwerwent resection anastomosis with primary anastomosis only in the same study period in terms of age, gender, comorbidity, diagnosis.

Eligibility criteria:
inclusion criteria: * all patients with high risk anastomoses
yf476 and type i gastric carcinoids

Conditions: Chronic Atrophic Gastritis; Hypergastrinaemia; Type I Gastric Carcinoids

Summary: the aim of the study is to find out if the experimental medicine, yf476, can make gastric carcinoids, a rare type of stomach tumour, shrink and disappear. gastric carcinoids occur mainly in patients with chronic atrophic gastritis (cag), a condition in which the acid-producing cells in the lining of the stomach can't make acid. acid production is controlled by gastrin, a hormone (chemical messenger) that's released into the bloodstream. if the stomach can't make acid, blood levels of gastrin rise. high blood levels of gastrin in patients with cag can cause other cells (ecl cells) in the lining of the stomach to grow and, over the years, to give rise to gastric carcinoids. gastric carcinoids are usually benign, but they can become malignant. therefore, patients with cag and gastric carcinoids have the inside of their stomach checked regularly, by gastroscopy, to see if the gastric carcinoids need removing surgically. a gastroscope is a thin (1 cm), flexible tube at end of which is a mini video camera, which enables the user to inspect the lining of the stomach and a 'snare' to take samples of tissue (biopsies). yf476 (netazepide) is a gastrin receptor antagonist (blocks the effects of gastrin), so it's a potential new medical treatment for gastric carcinoids in patients with cag. up to 10 of these patients will take yf476 daily for up to 12 weeks. if they benefit from that treatment, they may take yf476 daily for up to another 52 weeks. they'll make several outpatient visits for tests, including checks on the safety of yf476. at some of the visits, they'll have a gastroscopy. at each gastroscopy, the gastric carcinoids will be measured and biopsies taken for laboratory tests.


Eligibility criteria:
inclusion criteria: * patients known to have gastric carcinoids associated with chronic atrophic gastritis and hypergastrinaemia, and who attend the outpatient clinic of the investigator; * men, postmenopausal women, premenopausal women who have been sterilised by tubal ligation, hysterectomy or bilateral oophrectomy, or premenopausal women using reliable contraception: condom and spermicide or intrauterine device; * adults ≥ 18 years; * good general health; and * able to give fully-informed, written consent. exclusion criteria: * women who are pregnant, lactating or using a steroid contraceptive; * history of gastric surgery, apart from surgery for gastric carcinoids; * evidence of zollinger-ellison syndrome; * prolonged qtc interval (\>450 msec); * certain medicines and herbal remedies taken during the 7 days before visit 1; * previous treatment with somatostatin; or * participation in other clinical trials of unlicensed medicines within the previous 3 months.

Keywords: yf476 hypergastrinaemia netazepide gastric carcinoids
comparison of ischemic compression therapy and kinesiotaping in chronic neck pain

Conditions: Neck Pain

Summary: objective: the purpose of this study was to compare the effects of ischemic compression (ic) and kinesio taping (kt) treatments on blood flow, tissue stiffness and thickness, pain, and joint range of motion on the upper trapezius muscle of individuals with chronic neck pain. methods: in this study 22 individuals between the ages of 20-35 were randomly assigned to 3 groups: group1, which received ic; group2, received kt; group3 (control) received exercise, for 2 days and 4 weeks. pain was measured with vas, pain threshold with j-tech algometer, range of motion with baseline digital inclinometer, ultrasonographic measurements for blood flow, tissue stiffness and tissue thickness using acuson s3000. all measurements were performed twice; before and after treatment.


Eligibility criteria:
inclusion criteria: * a score ar least 3 and above 3 on the visual analogue scale * presence of palpable taut band and at least one trigger point on the taut band * presence of referred pain with palpation of the trigger point exclusion criteria: * analgesic use within the previous 24hours * history of cervical surgery * receiving myofascial pain treatment within the previous month of the study

Keywords: trapezius muscle trigger point ultrasonographic imaging blood flow chronic pain
study to investigate the efficacy and the safety of m518101 in psoriasis patients

Conditions: Plaque Psoriasis

Summary: this study is to investigate the efficacy and safety of m518101 in male and female plaque psoriasis patients with refractory plaques.


Eligibility criteria:
inclusion criteria: * who are able and willing to give signed informed consent * who are male or females aged between 18 and 65 years with plaque psoriasis confirmed by the investigator. * who have less than 20% of body surface area (bsa) afflicted with plaques * who are neither pregnant nor breast-feeding, nor plan to become pregnant during the study. exclusion criteria: * who have a history of allergy to vitamin d3 derivative preparations. * who have a history of relevant drug hypersensitivity. * who have a history of contact dermatitis induced by a topical medicine. * who are pregnant or lactating. * who have any renal or hepatic insufficiency, or clinically significant cardiac, renal or hepatic disease. * who have clinically relevant history or presence of any disease or surgical history other than psoriasis which is likely to affect the conduct of the study. * whose serum calcium levels exceed the upper limit of reference range * who have used any investigational medicinal product and/or participated in any clinical study within 24 weeks * who have been treated with systemic therapy within 8 weeks * who have been treated with biologics within 12 weeks * who have been treated with topical therapy during the wash-out and lead-in period.
orange juice consumption in patients with hepatitis c

Conditions: Chronic Infection

Summary: this study aimed to verify whether orange juice, source of citrus flavonoids and vitamin c, may contribute to the treatment of patients with chronic hepatitis c.

forty-three patients with chronic hepatitis c who were being treated with pegylated interferon combined with ribavirin, according to the clinical protocol and therapeutic guidelines for viral hepatitis c and co-infections of the brazilian health ministry were randomly divided into two parallel groups: (1) orange juice (n = 23), which were supplemented with orange juice (500 ml/d) for 8 weeks; (2) control group (n = 20) composed of patients that were not drinking orange juice regularly. the recruitment process began in february 2012, the intervention was carried out from may 2012 to july 2012, and the data analysis started in september 2012. the sample number took into account variances on total cholesterol with a type i error α = 0.05 and a type ii error β = 0.2 (80% power) (dourado et al., 2015). the minimum sample size should have 20 individuals per group (n = 40), considering an approximately 15% dropout rate. primary and secondary endpoints were the reduction of total cholesterol and modification of biochemical markers, respectively. kolmogorov smirnov and levene test assessed normality and homogeneity of data, respectively. assessment of the data was performed in all participants on the first and last day of the experiment. all the parameters were compared between the juice group and the control group using general linear model of repeated measures analysis. differences in baseline patients' characteristics between the two groups were analyzed by one-way analysis of variance (anova). the lsd signed rank post-test was used to assess significant changes in parameters after the start of treatment in each group, and the differences were considered statistically significant at p \< 0.05.

Eligibility criteria:
inclusion criteria: * detection of circulating hcv rna * negative hbv surface antigen * negative antibodies to hiv exclusion criteria: * co-infection with hepatitis b virus (hbv) * co-infection with hepatitis a virus (hav) * co-infection with human immunodeficiency virus (hiv) * presence of diabetes mellitus, * presence of ascites * elevation in serum ferritin levels

Keywords: orange juice chronic hepatitis c biochemical markers oxidative stress nutritional status antioxidants
a non interventional pilot study on machine learning for ild detection based on the patient data from digital devices in unresectable stage iii non-small cell lung cancer patients receiving durvalumab

Conditions: Carcinoma, Non-Small-Cell Lung

Summary: objective in this study is to investigate feasibility of developing machine-learning based model for the identification of future development of diagnosed grade 2 and higher ild and of disease progression in patients with unresectable stage iii nsclc receiving durvalumab

study design: multicentre, prospective, non-interventional pilot study data source(s): medical records, wearable devices, and mobile application. study population:patients treated durvalumab following chemoradiation therapy for stage iii unresectable nsclc in japan from the june 2021 to june 2022. they must fulfil all of the inclusion /exclusion criteria. exposure(s): dulvalumab outcome(s): disease progression, ild including radiation pneumonitis. sample size estimations : 150 patients statistical analysis: continuous variables will be reported as mean, median, standard deviation, iqr, maximum, and minimum. categorical variables will be summarized as absolute frequency and percentage. ninety-five percent confidence intervals (cis) will be presented where appropriate. time-to event for ild/disease progression will be estimated by kaplan-meir method. also, in the process of developing model, data production such as per-patient plots of the physiological data(multivariate time series) and physiological data before and after (in a shorter time-scale) the ild event per event will be considered.

Eligibility criteria:
inclusion criteria: * patient who provided written signed informed consent prior to the first study-specific procedures. * patient who receives durvalumab for unresectable stage iii nsclc at first time following chemoradiation therapy * patient whose performance status showed 0 or 1 prior to durvalumab treatment * patient who is able and willing to wear the devices daily for up to 6 months as instructed exclusion criteria: * patient under immunotherapy treatment other than durvalumab. * patient had received prior immunotherapy * patient under the interventional clinical studies using unapproved drugs or off-label use of drugs * patient who showed ild (including radiation pneumonitis) of grade 2 and higher, after consolidated chemoradiation therapy. * patient who is judged as not suitable for the study by the study site investigators, in terms of fitting wearable devices, presence of silicone or metallic allergy
behavioral treatment of weight gain in cf

Conditions: Cystic Fibrosis

Summary: the current study examines the efficacy of two treatments to help children with cystic fibrosis (cf) meet their dietary calorie requirements of 120% to 150% of the recommended daily allowance of energy and the effect of these treatments on weight gain and maintenance. one treatment provides children with cf and their parents nutrition education about the best foods for meeting their dietary needs. the second treatment gives children with cf and their families similar nutritional information plus behavioral parenting methods for motivating children to eat the recommended foods. children with cf and their families are seen weekly for 7 treatment sessions across 9 weeks for the active phase of treatment. families are then followed for 2 years after treatment in order to better understand how long the treatments are effective and to determine the health benefits of better nutrition status and weight gain.


Eligibility criteria:
inclusion criteria: * weight percentile for age or height below 40th for age and sex * pancreatic insufficiency exclusion criteria: * developmental delays * pseudomonas cepacia * supplemental enteral or parenteral nutrition

Keywords: nutrition behavior therapy cystic fibrosis
etravirine pharmacokinetics and hiv viral load in breast milk and plasma

Conditions: HIV

Summary: hiv positive pregnant women who receive potent combination antiretroviral therapy over at least the last trimester of pregnancy, and who have proper obstetric interventions and are able to avoid breast feeding, decrease the risk of having an infected infant to about 1%. breast milk hiv-1 rna (cell free) viral load is significantly associated with breast milk transmission, and a 2-fold increased risk of transmission associated with every 10-fold increase in breast milk viral load has been reported. in addition, cell associated virus (hiv dna) was associated with a significant increase in risk of transmission independent of the level of cell-free viral rna. however, multiple studies of hiv positive women giving birth have shown that exclusive breast-feeding carries a much lower risk of hiv transmission than mixed breast-feeding (defined as breast milk along with complementary food, other milk, and/or infant formula). the proposed study will measure the antiretroviral (arv) drug etravirine concentrations in blood and breast milk in postpartum hiv positive women on haart therapy. the short-term goal is to determine how much etravirine penetrates into breast milk, and whether it leads to undetectable hiv viral load in the breast milk and therefore has the potential to decrease the risk of transmission of hiv through breast milk. the long term goal is to see if breast milk hiv levels can be lowered sufficiently to prevent maternal to child transmission (mtct) of hiv in infants receiving only breast feeding in resource poor areas.


Eligibility criteria:
inclusion criteria: 1. hiv+ pregnant women on haart for the prevention of mtct w/ undetectable viral load at time of delivery (w/i 30 days of delivery). 2. 18 years and older 3. only women who are deemed by the physician as being capable of understanding that hiv positive women should not breastfeed will be approached. 4. life expectancy greater than 6 months 5. no known allergies to etravirine 6. willingness of subject to adhere to protocol requirements. exclusion criteria: 1. pregnant women with medical or psychological contraindications to breast milk expression. 2. requirements for prohibited medications: * arv: tipranavir/ritonavir, fosamprenavir/ritonavir, atazanavir/ritonavir, and protease inhibitors administered without ritonavir, nonnucleoside reverse transcriptase inhibitor (nnrtis). * alternative/cam: st. john's wort * anticonvulsants: phenobarbital, carbamazepine , phenytoin * anti-infectives: rifampin

Keywords: pharmacokinetics hiv breast milk